Integrating Quality of Life and Survival Outcomes in Cardiovascular Clinical Trials.
Aged
Aged, 80 and over
Aortic Valve Stenosis
/ diagnosis
Bayes Theorem
Endpoint Determination
Female
Health Status
Humans
Kaplan-Meier Estimate
Male
Patient Reported Outcome Measures
Quality of Life
Randomized Controlled Trials as Topic
Recovery of Function
Research Design
Severity of Illness Index
Time Factors
Transcatheter Aortic Valve Replacement
/ adverse effects
Treatment Outcome
health status
heart failure
quality of life
risk
transcatheter aortic valve replacement
Journal
Circulation. Cardiovascular quality and outcomes
ISSN: 1941-7705
Titre abrégé: Circ Cardiovasc Qual Outcomes
Pays: United States
ID NLM: 101489148
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
entrez:
14
6
2019
pubmed:
14
6
2019
medline:
19
5
2020
Statut:
ppublish
Résumé
Background Survival and health status (eg, symptoms and quality of life) are key outcomes in clinical trials of heart failure treatment. However, health status can only be recorded on survivors, potentially biasing treatment effect estimates when there is differential survival across treatment groups. Joint modeling of survival and health status can address this bias. Methods and Results We analyzed patient-level data from the PARTNER 1B trial (Placement of Aortic Transcatheter Valves) of transcatheter aortic valve replacement versus standard care. Health status was quantified with the Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 1, 6, and 12 months. We compared hazard ratios for survival and mean differences in KCCQ scores at 12 months using several models: the original growth curve model for KCCQ scores (ignoring death), separate Bayesian models for survival and KCCQ scores, and a Bayesian joint longitudinal-survival model fit to either 12 or 30 months of survival follow-up. The benefit of transcatheter aortic valve replacement on 12-month KCCQ scores was greatest in the joint-model fit to all survival data (mean difference, 33.7 points; 95% credible intervals [CrI], 24.2-42.4), followed by the joint-model fit to 12 months of survival follow-up (32.3 points; 95% CrI, 22.5-41.5), a Bayesian model without integrating death (30.4 points; 95% CrI, 21.4-39.3), and the original growth curve model (26.0 points; 95% CI, 18.7-33.3). At 12 months, the survival benefit of transcatheter aortic valve replacement was also greater in the joint model (hazard ratio, 0.50; 95% CrI, 0.32-0.73) than in the nonjoint Bayesian model (0.54; 95% CrI, 0.37-0.75) or the original Kaplan-Meier estimate (0.55; 95% CI, 0.40-0.74). Conclusions In patients with severe symptomatic aortic stenosis and prohibitive surgical risk, the estimated benefits of transcatheter aortic valve replacement on survival and health status compared with standard care were greater in joint Bayesian models than other approaches.
Identifiants
pubmed: 31189406
doi: 10.1161/CIRCOUTCOMES.118.005420
pmc: PMC6579042
mid: NIHMS1530203
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e005420Subventions
Organisme : NHLBI NIH HHS
ID : K23 HL116799
Pays : United States
Commentaires et corrections
Type : ErratumIn
Title corrected
Références
J Am Coll Cardiol. 2000 Apr;35(5):1245-55
pubmed: 10758967
Biometrics. 2001 Jun;57(2):383-8
pubmed: 11414560
Qual Life Res. 1992 Jun;1(3):219-24
pubmed: 1301130
Circulation. 2004 Aug 3;110(5):546-51
pubmed: 15262843
Health Qual Life Outcomes. 2004 Sep 16;2:49
pubmed: 15373945
Biometrics. 2004 Dec;60(4):892-9
pubmed: 15606409
Am Heart J. 2005 Oct;150(4):707-15
pubmed: 16209970
J Am Coll Cardiol. 2006 Feb 21;47(4):752-6
pubmed: 16487840
Circulation. 2007 Apr 17;115(15):1975-81
pubmed: 17420346
J Clin Oncol. 2010 Jun 1;28(16):2796-801
pubmed: 20439643
Stat Med. 2010 Jul 20;29(16):1724-34
pubmed: 20572123
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
Circulation. 2011 Nov 1;124(18):1964-72
pubmed: 21969017
Circ Heart Fail. 2013 Jan;6(1):61-7
pubmed: 23230306
Stat Methods Med Res. 2014 Oct;23(5):440-59
pubmed: 23427225
Circulation. 2013 Jun 4;127(22):2233-49
pubmed: 23648778
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
Stat Med. 2015 Jun 30;34(14):2181-95
pubmed: 24634327
Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):469-76
pubmed: 26307129
Circ Cardiovasc Interv. 2015 Dec;8(12):e002875
pubmed: 26643740
Qual Life Res. 2016 Dec;25(12):2977-2983
pubmed: 27650288
JAMA Cardiol. 2017 Dec 1;2(12):1315-1321
pubmed: 29094152
Circ Cardiovasc Qual Outcomes. 2017 Dec;10(12):e003268
pubmed: 29246883